INDSWIFT LABORATORIES
|
The Current P/E Ratio of INDSWIFT LABORATORIES is 38.97.
| Share Price | ₹367.4 | Oct 30,2026 |
| Market Cap | ₹3,247.8 Cr | |
| Earnings-TTM | ₹83.3 Cr | TTM-Consolidated Results |
| Price/Earnings | 38.97x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of INDSWIFT LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹3,247.8 Cr] as on Oct 30,2026
(/) Earnings [ ₹83.3 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 38.97x ]
Thus, for INDSWIFT LABORATORIES , the investors are currently willing to pay 38.97 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of INDSWIFT LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of INDSWIFT LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of INDSWIFT LABORATORIES
PE Ratio Performance Analysis for INDSWIFT LABORATORIES
- INDSWIFT LABORATORIES 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 7.41x.
- INDSWIFT LABORATORIES 's operated at median p/e ratio of 2.3x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, INDSWIFT LABORATORIES 's p/e ratio peaked in Mar2026 at 26.5x.
- INDSWIFT LABORATORIES 's p/e ratio hit its five-year low in Mar2022 of 0x.
How does INDSWIFT LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| INDSWIFT LABORATORIES | 83.35 | 38.97 | 3,247.8 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,037.20 | 38.66 | 426,662.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 88.17 | 257,903.0 |
| TORRENT PHARMACEUTICALS LTD | 2,099.00 | 84.00 | 176,306.0 |
| CIPLA LTD | 2,868.29 | 38.87 | 111,489.0 |
| DR REDDYS LABORATORIES LTD | 2,759.70 | 40.84 | 112,699.0 |
| MANKIND PHARMA LTD | 2,249.69 | 45.69 | 102,797.0 |
| LUPIN LTD | 5,551.01 | 16.55 | 91,870.2 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 27.62 | 124,089.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 26.00 | 96,536.9 |
| LAURUS LABS LTD | 1,333.75 | 96.90 | 129,243.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs INDSWIFT LABORATORIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 16.55x |
| Max industry PE | 96.90x |
| Median industry PE | 38.97x |
| Average industry PE | 49.30x |
You may also like the below Video Courses